Understanding the Stages of Corticobasal Degeneration (CBD)

Understanding the Stages of Corticobasal Degeneration (CBD)

Corticobasal Degeneration (CBD) is a rare, progressive neurological disorder characterized by the degeneration of certain regions of the brain. CBD primarily affects movement and cognitive functions, often presenting with an asymmetrical onset. Here’s how the progression of CBD can be understood:

Initial (Early) Stage:
  • Symptoms often start on one side of the body:
    • Asymmetric rigidity or stiffness in a limb.
    • Difficulty with voluntary movements (apraxia), particularly in using the affected limb.
    • Alien limb phenomenon, where the limb moves involuntarily or feels detached.
    • Cortical sensory loss, where patients might not recognize touch or limb position on the affected side.
  • Cognitive symptoms might include:
    • Language difficulties (aphasia), especially with grammar or speech production.
    • Executive dysfunction, impacting planning and decision-making.

Intermediate Stage:
  • The asymmetry in symptoms becomes more pronounced:
    • The affected side worsens, but symptoms might start to appear on the other side.
  • Motor symptoms expand:
    • Dystonia (muscle contractions causing twisting movements or postures) can become more severe.
    • Myoclonus, or sudden jerking movements, might develop.
    • Balance and coordination issues increase, heightening fall risk.
  • Cognitive and behavioral symptoms intensify:
    • There might be increased impulsivity, apathy, or inappropriate social behaviors.
    • Visual-spatial abilities could be impaired, making navigation or object recognition challenging.

Advanced (Late) Stage:
  • Mobility is significantly impaired:
    • Patients might be unable to walk or perform any voluntary movement due to the combination of rigidity, dystonia, and apraxia.
  • Speech becomes severely affected:
    • Communication might be reduced to minimal or non-verbal.
  • Swallowing difficulties (dysphagia) become a major concern, increasing the risk of aspiration.
  • Cognitive decline can become more profound:
    • Dementia symptoms might emerge or worsen, although cognitive impairment can be variable in CBD.
  • Autonomy is lost, leading to:
    • Total dependency on caregivers for all activities of daily living.

Note on Staging:
  • CBD’s progression is not as clearly staged as some other neurodegenerative diseases due to its variability and the diverse clinical presentations.
  • Life expectancy post-diagnosis can be anywhere from 6 to 10 years, influenced by factors like the initial severity of symptoms and the rate of progression.

Conclusion:
  • Understanding the stages of CBD helps in anticipating care needs, adapting living environments, and planning for future healthcare requirements.
  • There is no cure for CBD, and treatment focuses on symptom management, physical therapy, and strategies to cope with cognitive and behavioral changes.
  • Research continues into better understanding CBD, with trials exploring treatments that might slow progression or alleviate symptoms.
  • Awareness and education about CBD are vital for early diagnosis, improved caregiving, and advancing research towards potential therapies.
Back to blog

Leave a public comment:

Please note, comments need to be approved before they are published.

  • HOPE by Bhavna

    HOPE by Bhavna

    Remember the first timerobins sang in your garden,their delicate bodies pulsing with song,their hearts daring to rise, like yours.How the moon spilled its silver over your window,and your mother said,...

    HOPE by Bhavna

    Remember the first timerobins sang in your garden,their delicate bodies pulsing with song,their hearts daring to rise, like yours.How the moon spilled its silver over your window,and your mother said,...

  • Active Neurodegenerative Disease Clinical Trials (PSP, MSA, DLB, CBS, Parkinsonian Syndromes)

    Active Neurodegenerative Disease Clinical Trial...

    Progressive Supranuclear Palsy (PSP) Trials ClinicalTrials.gov ID: NCT06355531 – PROSPERPurpose: To evaluate whether FNP-223 slows disease progression in PSP, using the PSP Rating Scale (PSPRS) over 52 weeks. The trial also...

    Active Neurodegenerative Disease Clinical Trial...

    Progressive Supranuclear Palsy (PSP) Trials ClinicalTrials.gov ID: NCT06355531 – PROSPERPurpose: To evaluate whether FNP-223 slows disease progression in PSP, using the PSP Rating Scale (PSPRS) over 52 weeks. The trial also...

  • Recruiting participants for a groundbreaking study: “Assessing Cognitive Trajectories in Progressive Supranuclear Palsy Using Remote Computerized Reaction Time Tasks.”

    Recruiting participants for a groundbreaking st...

    Melbourne, Victoria – September 9, 2025 – The CCF Coleen Cunningham Foundation is partnering with researchers at the Alfred Hospital and Monash University to recruit participants for a groundbreaking study:...

    Recruiting participants for a groundbreaking st...

    Melbourne, Victoria – September 9, 2025 – The CCF Coleen Cunningham Foundation is partnering with researchers at the Alfred Hospital and Monash University to recruit participants for a groundbreaking study:...

  • WAITING By Bhavna

    WAITING By Bhavna

    For four years, she had lived with the unraveling of a rare brain disease. Progressive Supranuclear Palsy. Each step making her more dependent. Each fall more brutal. And each word...

    2 comments

    WAITING By Bhavna

    For four years, she had lived with the unraveling of a rare brain disease. Progressive Supranuclear Palsy. Each step making her more dependent. Each fall more brutal. And each word...

    2 comments
1 of 4